A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Abstract Tyrosine kinase inhibitors (TKIs) targeting EGFR-mutant lung cancers promote a range of tumor regression responses to yield variable residual disease, a likely incubator for acquired resistance. Herein, rapid transcriptional responses induced by TKIs early in treatment that associate with t...

Full description

Bibliographic Details
Main Authors: Natalia J. Gurule, Caroline E. McCoach, Trista K. Hinz, Daniel T. Merrick, Adriaan Van Bokhoven, Jihye Kim, Tejas Patil, Jacob Calhoun, Raphael A. Nemenoff, Aik Choon Tan, Robert C. Doebele, Lynn E. Heasley
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-021-00181-4

Internet

https://doi.org/10.1038/s41698-021-00181-4

Similar Items